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Abstract
Since 2000, under the Fifth and subsequent Framework Programmes, the European Commission has funded
research to spur the development of a malaria vaccine. This funding has contributed to the promotion of an
integrated infrastructure consisting of European basic, applied and clinical scientists in academia and small and
medium enterprises, together with partners in Africa. Research has added basic understanding of what is required
of a malaria vaccine, allowing selected candidates to be prioritized and some to be moved forward into clinical
trials. To end the health burden of malaria, and its economic and social impact on development, the international
community has now essentially committed itself to the eventual eradication of malaria. Given the current tentative
advances towards elimination or eradication of malaria in many endemic areas, malaria vaccines constitute an
additional and almost certainly essential component of any strategic plan to interrupt transmission of malaria.
However, funding for malaria vaccines has been substantially reduced in the Seventh Framework Programme
compared with earlier Framework Programmes, and without further support the gains made by earlier European
investment will be lost.
Background
Approximately one million people die each year from
malaria, mostly African children under the age of five and
pregnant women [1,2]. Malaria is, therefore, one of the
major global killer diseases and one of the world’s biggest
public health problems [1,3]. As malaria is mainly preva-
lent in low-income countries, it places a disproportionately
heavy economic burden on endemic countries, contribut-
ing to poverty and limiting economic development [1,4].
Malaria is a complex disease, which is transmitted to
humans through the bite of the female Anopheles mos-
quito inoculating protozoan parasites of the genus Plasmo-
dium. There are five types of human malaria, Plasmodium
falciparum, Plasmodium vivax, Plasmodium malariae,
Plasmodium ovale,a n dPlasmodium knowlesi,w i t h
P. falciparumand P. vivax being the most common and
P. falciparum being the most deadly [1,2].
A protective malaria vaccine that prevents or reduces
clinical malaria and associated mortality, as well as redu-
cing transmission, will have a major impact on global
human health and socioeconomic development. There is
considerable optimism that a malaria vaccine can be
developed, as immunity developed following natural
infection eventually prevents mortality and protects
against clinical disease [3].
A malaria vaccine developed by GlaxoSmithKline
( G S K )i sb e i n gt e s t e di nv a r i o u sA f r i c a nc o u n t r i e si n
Phase III clinical trials, following earlier relatively pro-
mising results indicating that perhaps 40-50% of
immunized children were protected against natural
infection for a significant period [5]. However, it seems
unlikely that GSK’s RTS, S pre-erythrocytic stage vac-
cine will generate higher levels of protection in Phase
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cal trials and it is doubtful whether the RTS, S vaccine
will have any impact on reducing malaria transmission.
To achieve elimination and eventual eradication, it is
clearly necessary to intensify the research and develop-
ment effort to obtain more protective, longer lasting
malaria vaccines, including vaccines which also protect
against other species of malaria, particularly the very
widely transmitted P. vivax.
History of European Commission funded malaria vaccine
projects
Under the Fifth Framework Programme (FP) plan for
Research and Technology Development (1998-2002),
the European Commission (EC) funded a broad range
of research activities related to the three major pov-
erty-related diseases (PRDs), HIV/AIDS, malaria and
tuberculosis. A total of 24 malaria projects were sup-
ported in this period, with a total budget of approxi-
mately € 29 million, of which around € 17 million was
dedicated to malaria vaccine projects [1,6]. Increased
funding for PRD research was provided in FP6 (2002-
2006) and a portfolio of 17 malaria projects was estab-
lished, with an overall budget of about € 64 million, of
which almost € 20 million was dedicated to malaria
vaccine projects [1].
In the current FP7 plan, (2007-2013), efforts were
made to capitalize on the advances achieved under FP6
by improved integration of basic malaria research with
more robust research and management structures to
translate research results into therapeutic drugs or vac-
cine candidates. By the end of 2010, halfway through
the FP7, a total of nearly € 80 million was earmarked
for malaria research. However, only around € 10 mil-
lion was earmarked for malaria vaccine research [1].
This probably reflected optimism that the GSK RTS, S
vaccine would translate well into the developing global
anti-malaria campaign and fuelled suggestions that
improved vaccines were not a priority.
The past and present EC funded malaria vaccine pro-
jects under FP5, FP6 and FP7 are listed in Table 1, 2 and 3
respectively [1].
Key successes, their impact and future perspectives
Vaccines are one of the most effective ways to protect
people against infectious diseases, and one of the most
cost-effective measures of public health. A malaria vac-
cine is unlikely to be developed if not supported by pub-
lic sector and charitable funding and international
public organizations, such as the EC [7].
Useful and significant advances have already been
achieved by several malaria vaccine projects funded by the
EC. A number of its malaria vaccine development projects
are in the clinical testing process and will report in the next
period. Current EC strategies clearly complement those of
other international agencies in this area and have the
potential to make a major impact on malaria vaccine devel-
opment projects. It is, therefore, critical that the EC con-
tinues to build on the major advances in understanding
immunity to malaria that have been achieved and on sev-
eral successes in raising immunogenicity of candidate vac-
cines. Rather than abandon this field, mechanisms for
continuing to develop more effective malaria vaccines by
building on the current RTS, S successes should be estab-
lished [7].
Conclusions
To maintain and consolidate the European vaccine devel-
opment infrastructure and exploit the considerable depth
of European expertise in this area, continued funding for
malaria vaccine research is essential. Doing otherwise will
ensure that European vaccine R&D teams, in both
Table 1 Malaria vaccine projects funded by the EC FP5
Project Project Coordinator Partner EC Contribution Duration Start
Acronym Type Name/Institution Numbers Euros Months Date
EUROMALVAC1 RS D. Arnot, University of Edinburgh, UK 10 3 500 000 36 01-02-2000
ATTMAL RS A. Waters, Leiden University, NL 5 1 492 640 36 01-03-2000
MALTRANS RS R. Sauerwein, Radboud University Nijmegen Medical Centre, NL 11 2 499 962 36 01-03-2000
AMVTNETHIC AM S. Jepsen, Statens Serum Institut, DK 1 220 000 36 01-04-2000
PAMVAC RS M. Klinkert, Bernhard-Nocht-Institute for Tropical Medicine, DE 6 1 503 210 36 01-09-2001
NEMLAR AM S. Jepsen, Statens Serum Institut, DK 1 70 000 36 01-12-2001
EMLI DM P. Druilhe, Institut Pateur, FR 7 1 462 733 36 01-01-2002
EMVI AM S. Jepsen, Statens Serum Institut, DK 2 700 000 36 01-08-2002
EUROMALVAC2 RS D. Arnot, University of Edinburgh, UK 12 3 700 044 36 01-09-2002
VIRIMAL RS P. Preiser, Medical Research Council, UK 5 1 196 180 36 01-09-2002
AMVTN/AMANET CA S. Jepsen, Statens Serum Institut, DK 16 1 000 000 36 01-11-2002
Total EC contribution under FP5 17 344 769
AM: Accompanying Measures, CA: Coordination Action, DM: Demonstration, RS: Research
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Europe risks becoming irrelevant in the global push
to eliminate malaria, just as this campaign gathers
momentum.
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Table 2 Malaria vaccine projects funded by the EC FP6
Project Project Coordinator Partner EC Contribution Duration Start
Acronym Type Name/Institution Numbers Euros Months Date
MALINV STREP L. Rénia, Département d’Immunologie, Institut Cochin, FR 5 587 000 24 01-06-2005
SME Malaria STREP R. Glück, Etna Biotech, IT 5 1 700 000 36 01-03-2006
EMVDA IP O. Leroy, European Vaccine Initiative, DE 15 13 500 000 63 01-12-2006
EURHAVAC SSA O. Leroy, European Malaria Vaccine Initiative, DK 1 260 000 24 01-12-2006
CILMALVAC STREP M. Hartmann, Cilian AG, DE 3 1 271 664 36 01-01-2007
PRIBOMAL STREP J. Goudsmit, Crucell Holland, NL 7 2 345 358 48 01-02-2007
Total EC contribution under FP6 19 664 022
IP: Integrated Project, SSA: Specific Support Actions, STREP: Specific Targeted Research Project.
Table 3 Malaria vaccine projects funded by the EC FP7
Project Project Coordinator Partner EC Contribution Duration Start
Acronym Type Name/Institution Numbers Euros Months Date
PreMalStruct S/M-SFRP B. Gamain, Institut Pasteur, FR 5 2 300 000 36 01-02-2008
STOPPAM S/M-SFRP M. Laurent, Institut de Recherche Pour le Development, FR 6 3 000 000 36 01-02-2008
INYVAX CA O. Leroy, European Vaccine Initiative, DE 7 932 335 36 01-02-2009
OPTIMALVAC CA O. Leroy, European Vaccine Initiative, DE 12 1 000 000 36 01-04-2009
REDMAL FRP R. Sauerwein, Radboud University Nijmegen Medical Centre, NL 6 2 999 998 48 01-03-2010
Total EC contribution under FP7 10 232 333
CA: Coordination Action, S/M-SFRP: Small or medium-scale focused research project.
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